A Phase 2A Trial of DT402 for Autism Spectrum Disorder
Trial details
- Registry ID
- NCT07303907
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as MDMA; MM402; R-MDMA
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Phase 2A Trial of DT402 for Autism Spectrum DisorderNCT07303907 | Definium Therapeutics US, Inc. | Phase 2 | Completed | 2026-09-16Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |